Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression

Functional Flow Cytometry to Predict PD‐L1 Conformational Changes

“…PD‐L1 assessment is currently performed by immunohistochemistry (IHC) assays and is associated with increased efficacy of immune‐checkpoint inhibitors used in therapy (Paver et al., 2021; Scheel & Schäfer, 2018). Nevertheless, PD‐L1 protein expression appears to be heterogeneous (Yue et al., 2018) and can be associated with contradictory clinical outcomes (Borghaei et al., 2020; Brahmer et al., 2015; Ding et al., 2022; McLaughlin et al., 2016). The PD‐L1 molecule has been described as having a conformational flexibility of 38° within the V and C domains of free and complexed PD‐L1, in specific flexible regions such as the C′′D loop and BC loop as well as Met115, which is postulated to occur to enable a better interaction to PD‐1 (Ahmed & Barakat, 2017; Lin et al., 2008).…”